Cargando…

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes

Heat shock protein 90 (Hsp90) is a molecular chaperone essential for the stability and function of multiple cellular client proteins, a number of which have been implicated in the pathogenesis of breast cancer. Here we undertook a comprehensive evaluation of the activity of ganetespib, a selective H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedland, Julie C., Smith, Donald L., Sang, Jim, Acquaviva, Jaime, He, Suqin, Zhang, Chaohua, Proia, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2013
Materias:	Preclinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913847/ https://www.ncbi.nlm.nih.gov/pubmed/23686707 http://dx.doi.org/10.1007/s10637-013-9971-6

Ejemplares similares

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
por: He, Suqin, et al.
Publicado: (2014)

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
por: Proia, David A., et al.
Publicado: (2012)

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
por: HE, SUQIN, et al.
Publicado: (2012)

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
por: Smith, Donald L., et al.
Publicado: (2014)

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
por: Gomez-Casal, Roberto, et al.
Publicado: (2015)

Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
por: Proia, David A., et al.
Publicado: (2011)

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
por: Lin, Shu-Fu, et al.
Publicado: (2017)

HSP-90 Inhibitor Ganetespib is Synergistic with Doxorubicin in Small Cell Lung Cancer
por: Lai, Chien-Hao, et al.
Publicado: (2013)

Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

Corrigendum: Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice
por: Youssef, Mahmoud E., et al.
Publicado: (2023)

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
por: Lang, Julie E., et al.
Publicado: (2022)

The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine
por: Lazenby, M., et al.
Publicado: (2015)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
por: London, Cheryl A., et al.
Publicado: (2011)

Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
por: Wu, Xinqi, et al.
Publicado: (2013)

HSP90 Inhibitor Ganetespib (STA-9090) Inhibits Tumor Growth in c-Myc-Dependent Esophageal Squamous Cell Carcinoma
por: Guan, Liuliu, et al.
Publicado: (2020)

Ganetespib radiosensitization for liver cancer therapy
por: Chettiar, Sivarajan T., et al.
Publicado: (2016)

An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein
por: McCready, Jessica, et al.
Publicado: (2014)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib
por: Landmann, H, et al.
Publicado: (2014)

The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus
por: Liu, Yuan, et al.
Publicado: (2015)

In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines
por: Klameth, Lukas, et al.
Publicado: (2017)

Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer
por: Liu, H, et al.
Publicado: (2015)

Ganetespib: research and clinical development
por: Jhaveri, Komal, et al.
Publicado: (2015)

Phosphorylation of Hsp20 Promotes Fibrotic Remodeling and Heart Failure
por: Gardner, George T., et al.
Publicado: (2019)

The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer
por: Eyermann, Christopher E., et al.
Publicado: (2021)

Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments
por: Scutigliani, Enzo M., et al.
Publicado: (2022)

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
por: Goldman, Jonathan W, et al.
Publicado: (2013)

BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance
por: Kuilman, Midas M., et al.
Publicado: (2022)

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
por: Lips, E. H., et al.
Publicado: (2013)

Intrinsic subtypes in Ethiopian breast cancer patient
por: Desalegn, Zelalem, et al.
Publicado: (2022)

Retrospective analysis of metastatic behaviour of breast cancer subtypes
por: Savci-Heijink, C. Dilara, et al.
Publicado: (2015)

The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer
por: Hu, Jiayue, et al.
Publicado: (2023)

The broad stroke of Hsp90 inhibitors: painting over the RAF inhibitor paradox
por: Vido, Michael, et al.
Publicado: (2015)

Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients
por: Engstrøm, M. J., et al.
Publicado: (2013)

Evolution of kinase polypharmacology across HSP90 drug discovery
por: Antolin, Albert A., et al.
Publicado: (2021)

Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns
por: Bardowell, Sabrina A., et al.
Publicado: (2013)

The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence
por: Jansson, Sara, et al.
Publicado: (2018)

Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry
por: Wirtz, Ralph M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c7tmaq8e93lmksjk51bqb5dchu